| Press releases

Formycon Plans Change in New SME Stock Exchange Segment “Scale”

Formycon plans, with effect from March 1, 2017, to switch to Deutsche Börse AG’s new stock exchange segment “Scale” for small and medium-sized enterprises (SMEs).


DVFA Spring Conference

May 8 – 10, 2017; Frankfurt/Germany

Financial reports

Half-Year Report 2016

Published on:
September 20, 2016

  • teaser-wachstumschampion-en
  • Forschungssiegel_Teaser_Webseite-en
  • buchner_en
  • pipeline-en-teaser
  • Foto_MedicineMaker_Powerlist
  • slider04
  • slider06

Formycon is a leading independent pure play developer of biosimilars and has become a recognized innovator in this field. The company has extensive experience in the development of complex biological molecules. Formycon’s specialist expertise allows the company to develop high-quality biosimilars that meet the strict regulatory requirements of highly regulated markets such as Europe and the United States. Formycon currently has four biosimilars under development, with further product candidates already identified. Two biosimilar candidates have been licensed out to Santo Holding GmbH.